Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for InMed Pharmaceuticals (INM) over the last 6 years, with Jun 2025 value amounting to -$249,728.

  • InMed Pharmaceuticals' Change in Accured Expenses rose 57.34% to -$274,066 in Q3 2025 from the same period last year, while for Sep 2025 it was $118,598, marking a year-over-year increase of 442.51%. This contributed to the annual value of -$249,728 for FY2025, which is 651.50% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Change in Accured Expenses of -$249,728 as of FY2025, which was down 651.50% from $45,282 recorded in FY2024.
  • InMed Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $346,685 during FY2021, with a 5-year trough of -$811,599 in FY2022.
  • For the 3-year period, InMed Pharmaceuticals' Change in Accured Expenses averaged around -$336,992, with its median value being -$249,728 (2025).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 105.61% in 2024, then tumbled by 651.50% in 2025.
  • InMed Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $346,685 in 2021, then crashed by 334.10% to -$811,599 in 2022, then grew by 0.62% to -$806,530 in 2023, then skyrocketed by 105.61% to $45,282 in 2024, then crashed by 651.50% to -$249,728 in 2025.